|
HADS Anxiety
|
Pre-treatment
| | |
|
Post-treatment
|
− 2.67 (− 4.32 to − 1.03)
|
0.002
|
|
Follow-up
|
− 1.84 (− 3.56 to − 0.13)
|
0.04
|
|
HADS Depression
|
Pre-treatment
| | |
|
Post-treatment
|
− 1.98 (− 3.41 to − 0.55)
|
0.007
|
|
Follow-up
|
− 1.43 (− 2.92 to 0.07)
|
0.06
|
|
HADS
|
Pre-treatment
| | |
|
Post-treatment
|
− 4.65 (− 7.27 to − 2.03)
|
0.0006
|
|
Follow-up
|
− 3.20 (− 5.92 to − 0.48)
|
0.02
|
|
WHO DAS
|
Pre-treatment
| | |
|
Post-treatment
|
− 3.81 (− 6.59 to − 1.04)
|
0.008
|
|
Follow-up
|
− 4.44 (− 7.34 to − 1.55)
|
0.003
|
|
PCL
|
Pre-treatment
| | |
|
Post-treatment
|
− 3.30 (− 8.71 to 2.12)
|
0.23
|
|
Follow-up
|
− 5.17 (− 11.08 to − 0.33)
|
0.04
|
|
PHQ
|
Pre-treatment
| | |
|
Post-treatment
|
− 2.51 (− 4.96 to − 0.06)
|
0.04
|
|
Follow-up
|
− 3.04 (− 5.32 to − 0.76)
|
0.01
|
|
Days of these difficulties present
|
Pre-treatment
| | |
|
Post-treatment
|
− 4.33 (− 7.90 to − 0.77)
|
0.02
|
|
Follow-up
|
− 2.84 (− 6.47 to 0.79)
|
0.12
|
|
Days of total disability
|
Pre-treatment
| | |
|
Post-treatment
|
− 2.51 (− 5.18 to 0.15)
|
0.06
|
|
Follow-up
|
− 1.69 (− 4.41 to 1.02)
|
0.22
|
|
Days of activity reduce
|
Pre-treatment
| | |
|
Post-treatment
|
− 3.15 (− 6.41 to 0.10)
|
0.06
|
|
Follow-up
|
− 1.95 (− 5.27 to 1.37)
|
0.25
|
|
Perceived social support
|
Pre-treatment
| | |
|
Post-treatment
|
4.45 (− 1.05 to 9.95)
|
0.11
|
|
Follow-up
|
2.52 (− 3.22 to 8.27)
|
0.39
|
|
PSYCHLOPS
|
Pre-treatment
| | |
|
Post-treatment
|
− 2.58 (− 4.39 to − 0.77)
|
0.006
|
|
Follow-up
|
− 1.66 (− 3.54 to 0.23)
|
0.08
|
